Follow-up Results of
Aged
Antiviral Agents
/ therapeutic use
Carcinoma, Hepatocellular
/ etiology
Drug Therapy, Combination
Female
Genotype
Hepacivirus
/ genetics
Hepatitis C
/ complications
Humans
Liver Cirrhosis
/ etiology
Liver Neoplasms
/ etiology
Male
Middle Aged
RNA, Viral
/ analysis
Ribavirin
/ therapeutic use
Sofosbuvir
/ therapeutic use
Treatment Outcome
HCC
HCV
RAS
SVR
late relapse
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
13
05
2019
revised:
04
06
2019
accepted:
10
06
2019
entrez:
3
7
2019
pubmed:
3
7
2019
medline:
10
7
2019
Statut:
ppublish
Résumé
We examined treatment the efficacy and data on long-term outcomes in real-world Japanese patients infected with hepatitis C virus (HCV) genotype 2 treated with 12-week sofosbuvir/ribavirin combination therapy. In a total of 86 patients who were treated with sofosbuvir/ribavirin, sustained virological response (SVR) rates and long-term-outcomes were retrospectively analyzed. The adherence to this combination therapy was 98.8%. The rates of SVR at week 24 (SVR24) achieved with this treatment according to the 'intention-to-treat' and 'per-protocol' analyses were 89.5% and 96.2%, respectively. Two patients who experienced relapse did not have any previously reported resistance-associated substitutions in the HCV non-structural protein 5B (NS5B) polymerase region. We did not observe any patients who experienced late relapse but did observe that 50% and 1.3% of patients with and without a previous history of hepatocellular carcinoma (HCC), respectively, developed HCC after achieving SVR24 (with a mean follow-up period of 2.7±0.8 years). Patients with SVR should be carefully followed-up to screen for the occurrence of HCC, although it is infrequent.
Sections du résumé
BACKGROUND
BACKGROUND
We examined treatment the efficacy and data on long-term outcomes in real-world Japanese patients infected with hepatitis C virus (HCV) genotype 2 treated with 12-week sofosbuvir/ribavirin combination therapy.
PATIENTS AND METHODS
METHODS
In a total of 86 patients who were treated with sofosbuvir/ribavirin, sustained virological response (SVR) rates and long-term-outcomes were retrospectively analyzed.
RESULTS
RESULTS
The adherence to this combination therapy was 98.8%. The rates of SVR at week 24 (SVR24) achieved with this treatment according to the 'intention-to-treat' and 'per-protocol' analyses were 89.5% and 96.2%, respectively. Two patients who experienced relapse did not have any previously reported resistance-associated substitutions in the HCV non-structural protein 5B (NS5B) polymerase region. We did not observe any patients who experienced late relapse but did observe that 50% and 1.3% of patients with and without a previous history of hepatocellular carcinoma (HCC), respectively, developed HCC after achieving SVR24 (with a mean follow-up period of 2.7±0.8 years).
CONCLUSION
CONCLUSIONS
Patients with SVR should be carefully followed-up to screen for the occurrence of HCC, although it is infrequent.
Identifiants
pubmed: 31262913
pii: 39/7/3855
doi: 10.21873/anticanres.13535
doi:
Substances chimiques
Antiviral Agents
0
RNA, Viral
0
Ribavirin
49717AWG6K
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3855-3862Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.